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S U M M A R Y
O B J E C T I V E : To determine the optimal tuberculosis
(TB) management strategy for children living in peri-
urban, resource-limited settings.
D E S I G N : We compared TB treatment outcomes among
children aged 0–15 years receiving doorstep care (n¼82)
with those of a historical group (n¼97) receiving clinic-
based care.
R E S U LT S : The doorstep care and clinic-based groups
had similar age and sex profiles; treatment default rates
were 3.7% (3/82) vs. 38.1% (37/97, P , 0.0001),
treatment completion rates were 65.9% (54/82) vs.
51.6% (50/97, P ¼ 0.01), and cure rates were 13.4%
(11/82) vs. 2.1% (2/97), respectively (P , 0.0001).
C O N C L U S I O N : Children living in peri-urban communi-
ties had improved TB treatment outcomes with doorstep
care.
K E Y W O R D S : tuberculosis; doorstep care; peri-urban;
TB; South Africa
IN 2012, APPROXIMATELY 6% of the global
tuberculosis (TB) burden occurred in children aged
0–15 years.1 While TB mortality rates among human
immunodeficiency virus (HIV) infected children is
largely unknown, the 74 000 TB deaths among HIV-
negative children accounted for 8% of global TB
deaths.1 In South Africa, childhood TB accounts for
15–20% (47 571 cases) of the total number of TB
cases, and is among the top five causes of death in
children aged ,15 years.2 In 2006, 29 801 TB cases
were reported among children aged 0–7 years in
South Africa, accounting for 8% of all TB cases
notified.3 The TB impact on child health impedes
South Africa’s efforts to attain the Millennium
Development Goals (MDG) 4 and 6 pertaining to
child health.4
The optimal management strategy for childhood
TB is largely unknown. The World Health Organiza-
tion’s (WHO’s) Stop TB Strategy, which advocates for
directly observed treatment (DOT) under decentral-
ised TB care,1 makes no special considerations for
children. Resource constraints have meant that clinic-
based TB care remains the routine approach, even
among children.5 Despite the successes of DOT,5 a
meta-analysis suggested that this strategy was not
superior to self-administration.6 Studies evaluating
the impact of alternative approaches to childhood TB
care in this setting are scarce.
We compared TB treatment outcomes among
children receiving doorstep TB care with those of a
historical group receiving clinic-based care in the
same peri-urban community.
METHODS
We conducted a retrospective analysis of clinic
records of 82 children aged 0–15 years enrolled in a
pilot Centre for the AIDS Programme of Research in
South Africa (CAPRISA) doorstep TB care pro-
gramme from 2008 to 2011. This was compared
with a historical group of 92 children from the same
peri-urban community receiving clinic-based TB care
from 2005 to 2008. This peri-urban community
included residents from low-cost state housing and
adjacent informal squatter settlements.
The doorstep TB care programme was a health care
intervention that formed part of the CAPRISA
community-based treatment programme, aimed at
enhancing TB treatment access and adherence. A
total of 516 adult and childhood ambulatory TB cases
were referred for doorstep TB on presentation at
either one of the two local primary health care clinics
for TB diagnosis or treatment follow-up. TB was
diagnosed based on sputum analysis and chest X-ray.
Following counselling, parents or guardians provided
consent for the enrolment of the children into care.
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The addresses were then verified. Trained community
care givers or nurses supervised two to three home
visits per week and recorded basic clinical history,
evaluated treatment adherence, completed the TB
treatment card, offered TB-specific health education,
addressed issues relating to poor adherence, dis-
pensed TB medication and arranged follow-up visits.
All patients and their guardians were counselled on
the need for TB screening in the household and for
HIV testing, and where permission for testing was
obtained, HIV testing and TB screening were
performed.
Anti-tuberculosis treatment was monitored using a
doorstep TB care card. Very sick patients were visited
by a professional nurse on request, and were referred
to another health facility, if required, along with those
patients who wished to relocate. These patients were
documented as transferred out. All patients visited
the clinic at the end of the intensive and continuous
phases of anti-tuberculosis treatment for sputum and
clinical evaluation.
A total of 560 adult and childhood TB cases were
receiving clinic-based care. The clinic-based group
received care from the local primary health care clinic
per routine practice. Patients were expected to visit
the clinic once a month to collect their medications.
Clinic cards contained only basic demographic and
TB outcome data. A follow-up date was given on the
patient’s clinic card. Patients could visit the clinic if
they felt unwell or had queries regarding their
medication.
Both groups were administered the standard treat-
ment regimen, i.e., 2 months of rifampicin (RMP),
isoniazid (INH), pyrazinamide and ethambutol, fol-
lowed by 4 months of INH and RMP. Multidrug-
resistant, extensively drug-resistant and extra-pulmo-
nary TB cases were not included in this study.
Treatment outcomes for both groups were defined
as recommended in the 2014 South African TB
Control Programme Guidelines and the 2013 WHO
TB outcomes classification.7,8
Statistical analysis
Data are presented as proportions. A sample t-test
and a sample binomial test were used to compare TB
treatment outcome data between groups. Statistical
analyses were performed using SAS, version 9.2
(Statistical Analysis System, Cary, NC, USA).
The study was approved by the University of
KwaZulu-Natal Biomedical Research Ethics Com-
mittee, Durban, South Africa (Ref: E248/05).
RESULTS
Baseline characteristics
Overall, childhood TB accounted for 82 of 516
(15.9%) cases in the doorstep TB care group and 97/
560 (17.3%) cases under the clinic-based care
programme. In the doorstep and clinic-based care
programmes, the mean age was respectively 3.9 years
(interquartile range [IQR] 1–5) (P ¼ 0.91) vs. 3.5
years (IQR 1–5) (P ¼ 0.51); most children were
between the ages of 1 and 6 years (64.6% vs. 69.2%),
with a male predominance (53.7% vs. 55.7%) (Table
1).
TB treatment outcomes
In the doorstep TB and clinic-based TB care
programmes, treatment success (cure and comple-
tion) rates were respectively 79.3% (65/82) and
53.7% (52/97) (P , 0.0001), treatment completion
rates were 65.9% (54/82) and 51.6% (50/97) (P ¼
0.01) and cure rates were 13.4% (11/82) and 2.1%
(2/97), (P , 0.0001) (Table 2). Children receiving
doorstep TB care had significantly lower treatment
default rates (3/82, 3.7%) than those who received
clinic-based TB care (37/97, 38.1%, P , 0.0001).
Transfer out and relocation occurred more frequently
in the doorstep vs. the clinic-based care group
(respectively 5 [6.1%] vs. 3 [3.1%] and 9 [11%] vs.
4 [4.1%]. Patients who transferred out or relocated
did not have their TB treatment outcomes evaluated.
There was one death among the patients receiving
clinic-based care.
Age-stratified TB outcomes
Treatment completion outcomes showed the greatest
improvement among children aged ,1 year under
doorstep TB care (10/13, 76.9%) vs. clinic-based care
Table 1 Baseline characteristics comparing children receiving







n (%) P value
Male 44 (53.7) 54 (55.7) 0.80
Age, years
,1 13 (15.9) 13 (13.5) 0.60
1–6 53 (64.6) 67 (69.1) 0.45
7–15 16 (19.5) 17 (17.6) 0.72
TB¼ tuberculosis.
Table 2 Childhood TB treatment outcomes in the doorstep TB









n (%) P value
Treatment success 65 (79.3) 52 (53.7) ,0.0001
Cure 11 (13.4) 2 (2.1) ,0.0001
Completed treatment 54 (65.9) 50 (51.6) 0.01
Defaulted 3 (3.7) 37 (38.1) ,0.0001
Transferred out 5 (6.1) 3 (3.1) 0.22
Relocated 9 (11.0) 4 (4.1) 0.01
Death 0 1 (1.0) —
TB¼ tuberculosis.
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(1/13, 7.5%) (Table 3). The greatest reduction in
treatment default rates was among children aged 7–
12 years, from 46.7% (7/15) among those on clinic-
based care to 0% (0/11) among those on doorstep TB
care. Provision of doorstep TB care had no impact
among the 7–12 and 13–15 year age groups who
relocated or transferred out, where both outcomes
increased from 6.7% (1/15) in clinic-based care to
9.1% (1/11) in doorstep care.
HIV co-infection
Data on the HIV status of the patients were only
available for the doorstep TB care group. Of 82
patients, 36 (44%) had known HIV status, 15 of
whom were verified by the health care worker. There
were 21/82 (26%) non-HIV-infected (17 unverified)
children. Of the 46 children (56%) not tested for
HIV, the guardians of 30 children said that the child
could be tested after completion of TB treatment.
These numbers are too small to comment on the
association of HIV co-infection with TB treatment
outcomes.
DISCUSSION
The improved treatment success rates among children
receiving doorstep TB care compared to clinic-based
care suggest that the former should be the preferred
strategy for childhood TB management. The greatest
impact on the treatment success rates was achieved in
the ,1-year age group (Table 3). Limited data are
available for a comparison of TB outcomes, and
specifically treatment completion and treatment
default rates, among children aged ,1 year and those
aged 7–12 years. Available age-stratified TB outcome
data from a retrospective study of over 2000 children
conducted in Ethiopia demonstrated similar TB
treatment completion, default and transfer out rates
among children aged ,4 years compared to rates
among children aged ,6 years in our study.9 While
the Ethiopian study also demonstrated significantly
higher mortality among children aged ,5 years (P ,
0.001) and among those with HIV co-infection (P ,
0.001),9 we have insufficient data to make this
comparison.
We attribute the extremely low TB cure rates in our
population to the recognised challenges associated
with detecting TB in very young children.1 Although
the treatment success rate among those receiving
doorstep TB care was higher than among those
receiving clinic-based care, they do not reach the
WHO and country target of 85%.1,7 A study from
India among children aged 712 years enrolled in the
more resource-intensive conventional DOTS pro-
gramme showed a 94.6% treatment success rate.10
The low TB treatment success rate among children
enrolled in clinic-based care, as seen in this study, is in
line with findings from studies conducted in Bot-
swana, Malawi and India.11,12 In the South African
context, where childhood TB accounts for approxi-
mately 13% of the total South African TB burden,1
children are a vulnerable group requiring attention.
Current TB management efforts are largely clinic-
based, and will not enable us to reach the MDG 4 and
6 targets for child health.
While the impact of HIV co-infection, malnutri-
tion, immunosuppression and TB drug resistance13
on TB outcomes were not evaluated in this study, we
highlight notable improvements in TB treatment
outcomes and a significant reduction in the treatment
default rate among children accessing doorstep anti-
tuberculosis treatment. More patients had a record of
transfer out or relocation in the doorstep TB care
programme as opposed to clinic-based care, most
likely due to reporting bias. This is also evident from
the higher rates of transfer out and relocation.
Furthermore, TB outcomes in these patients were
not evaluated in both study groups due to resource
constraints. It is reasonable to suggest that migration
patterns typical of peri-urban populations, as seen
elsewhere in India and globally,5,14 influence the
recording of treatment outcomes.
As the risk of progression to active TB is greatest
among children aged ,2 years,15 it was not surprising
to find that approximately 81% of TB cases in this
study were aged 76 years, in line with other studies
Table 3 Age-stratified TB treatment outcomes for doorstep TB care and clinic-based TB care
Doorstep TB care Clinic-based TB care
n (%) n (%)
Age group, years ,1 1–6 7–12 13–15 ,1 1–6 7–12 13–15
Treatment outcome
Cured 1 (7.7) 4 (7.5) 4 (36.4) 2 (40) 0 0 2 (13.3) 0
Completed treatment 10 (76.9) 37 (69.8) 5 (45.5) 2 (40) 1 (7.7) 44 (65.7) 4 (26.7) 1 (50)
Defaulted 1 (7.7) 2 (3.8) 0 0 10 (76.9) 19 (28.4) 7 (46.7) 1 (50)
Transferred out 0 4 (7.5) 1 (9.1) 0 0 2 (3) 1 (6.7) 0
Relocated 1 (7.7) 6 (11.3) 1 (9.1) 1 (20) 1 (7.7) 2 (3) 1 (6.7) 0
Death 0 0 0 0 1 (7.7) 0 0 0
Total 13 (100) 53 (100) 11 (100) 5 (100) 13 (100) 67 (100) 15 (100) 2 (100)
TB¼ tuberculosis.
TB treatment outcomes in children 237
conducted elsewhere.9,16 The 2012 South African
Integrated Schools’ Health Policy, which uses schools
as a first point of care,17 therefore misses the majority
of childhood TB cases. The optimal mechanism for
detection of these cases under the health programme
would be via the Integrated Management of Child-
hood Illnesses programme and the Expanded Pro-
gramme of Immunization. In addition, initiatives to
address retention gaps are necessary even with
doorstep care programmes. Patient education on
disclosing pending relocation, improved communica-
tion between patients and health care workers
(HCWs), and between HCWs of different facilities,
will enable seamless transfer of patients between
facilities.
Limitations
There are important limitations in this study. The
generalisability of our findings is limited, as the
study was restricted to selected clinics serving a
geographically defined population. Due to inade-
quate documentation, we are unable to report on
outcomes by TB site and smear status or on efforts in
household TB contact tracing. In addition, HIV
testing rates in children were low due to challenges
in obtaining consent from parents and guardians,
making it impossible to obtain a true estimate of the
impact of HIV co-infection on TB outcomes in this
group. The inability to determine cure and mortality
rates among the clinic-based care group was likely
due to poor TB tracing systems and lack of
programme mechanisms for the detection of treat-
ment default. While the number of treatment
defaulters in the doorstep care programme was
lower, no further follow-up of treatment defaulters
and those who transferred out was possible in either
group due to poor patient communication of
impending relocation and restricted geographic
coverage of the programme. Additional potential
bias include ascertainment bias, as data were
collected over different periods of time in the two
groups, and due to the retrospective nature of the
analysis of the clinic-based care group, only demo-
graphic data for sex and age were available for
comparison. Further research evaluating the impact
of doorstep care on TB outcomes is required.
Analysis stratified by HIV status, nutrition level,
clinical presentation and site of TB, and availability
of mycobacteriological data and treatment features,
will provide further data on the utility and general-
isability of such a strategy to resource-limited
settings, where these co-existing features are com-
mon.
In conclusion, doorstep TB care led to an increase
in TB cure and completion rates among children as
compared to clinic-based care; however, treatment
success rates remain below WHO targets. The system
should be strengthened to ensure retention of children
in TB treatment programmes.
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R E S U M E
O B J E C T I F : Déterminer la meilleure stratégie de prise en
charge de la tuberculose (TB) pour les enfants vivant
dans des zones périurbaines aux ressources limitées.
S C H É M A : Nous avons comparé les résultats du
traitement de la TB chez des enfants âgés de 0–15 ans,
bénéficiant de soins à domicile (n ¼ 82) à un groupe
historique (n ¼ 97) recevant leur traitement dans un
centre de santé.
R É S U LTAT S : Le groupe recevant les soins à domicile et
le groupe traité en centre de santé avaient une répartition
par âge et par sexe similaire ; les taux d’abandon ont été
de 3,7% (3/82) contre 38,1% (37/97 ; P , 0,0001), les
taux d’achèvement du traitement ont été de 65,9% (54/
82) contre 51,6% (50/97 ; P ¼ 0,01) et les taux de
guérison ont été de 13,4% (11/82) contre 2,1% (2/97),
respectivement (P , 0,0001).
C O N C L U S I O N : Les enfants vivant dans des
communautés périurbaines ont eu de meilleurs
résultats du traitement antituberculeux avec une prise
en charge à domicile.
R E S U M E N
O B J E T I V O: Determinar la estrategia óptima de
tratamiento de la tuberculosis (TB) en los niños que
viven en los entornos periurbanos de recursos limitados.
M É T O D O S: Se compararon los desenlaces del
tratamiento antituberculoso en los niños de edad de 0–
15 años que recibieron atención domiciliaria (n ¼ 82)
con un grupo de referencia histórico que recibió atención
en un servicio ambulatorio (n¼ 97).
R E S U LTA D O S: El grupo de atención domiciliaria y el
grupo que acudió al servicio ambulatorio presentaron
caracterı́sticas semejantes de edad y sexo; las tasas de
abandono del tratamiento fueron 3,7% (3/82) contra
38,1% (37/97), respectivamente (P , 0,0001); las tasas
de compleción del tratamiento fueron 65,9% (54/82) y
51,6% (50/97; P¼ 0,01); y las tasas de curación 13,4%
(11/82) contra 2,1% (2/97; P , 0,0001).
C O N C L U S I Ó N: Los niños que viven en comunidades
periurbanas alcanzan desenlaces más favorables del
tratamiento de la TB cuando reciben atención
domiciliaria.
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